This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
Evidence-based recommendations on rapid tests for group A streptococcal (strep A) infections in people aged 5 and over with a sore throat
Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting
Evidence-based recommendations on integrated multiplex polymerase chain tests for identifying gastrointestinal pathogens in suspected gastroenteritis
Evidence-based recommendations on new generation computed tomography (CT) scanners for cardiac imaging for suspected or known coronary artery disease
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy
Evidence-based recommendations on multi frequency bioimpedance devices to guide fluid management for people with chronic kidney disease having dialysis
Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer
Evidence-based recommendations on biomarker tests (Actim Partus, PartoSure, Rapid fFN 10Q Cassette) to diagnose preterm labour in women with intact membranes
Evidence-based recommendations on DYSIS colposcope with DYSISmap and ZedScan I for assessing suspected cervical abnormalities in people having colposcopy
Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer
Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care
Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis
Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults
NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung
NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..
Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma